BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 11965603)

  • 1. Somatostatin receptor imaging.
    Kwekkeboom DJ; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):84-91. PubMed ID: 11965603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide receptor imaging and therapy.
    Kwekkeboom D; Krenning EP; de Jong M
    J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
    Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
    J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview.
    Kwekkeboom DJ; Krenning EP
    Eur Radiol; 1997; 7(7):1103-9. PubMed ID: 9265684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).
    Olsen JO; Pozderac RV; Hinkle G; Hill T; O'Dorisio TM; Schirmer WJ; Ellison EC; O'Dorisio MS
    Semin Nucl Med; 1995 Jul; 25(3):251-61. PubMed ID: 7570044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
    Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
    [No Abstract]   [Full Text] [Related]  

  • 7. [Preliminary results on the use of scintigraphy with radiolabelled octreotide as diagnostic method in neuroendocrine and nonendocrine neoplasms of the lung].
    Oliaro A; Filosso PL; Bellò M; Casadio C; Muni A; Angusti T; Masaneo I; Bisi G; Maggi G
    Minerva Chir; 1997 Nov; 52(11):1335-8. PubMed ID: 9489331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
    Banzo J; Abós MD; Prats E; García F; Razola P
    Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
    [No Abstract]   [Full Text] [Related]  

  • 9. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
    Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
    J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
    Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
    Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 111In-octreotide scintigraphy in small cell lung cancer.
    Semprebene A; Ferraironi A; Franciotti G; Venturo I; Giunta S; Lopez M; Maini CL
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):108-10. PubMed ID: 9002764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results.
    Krenning EP; Kwekkeboom DJ; Oei HY; de Jong RJ; Dop FJ; Reubi JC; Lamberts SW
    Ann N Y Acad Sci; 1994 Sep; 733():416-24. PubMed ID: 7978890
    [No Abstract]   [Full Text] [Related]  

  • 13. Somatostatin receptors and breast cancer.
    van Eijck CH; Kwekkeboom DJ; Krenning EP
    Q J Nucl Med; 1998 Mar; 42(1):18-25. PubMed ID: 9646641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
    Chiti A; Spinelli A; Bombardieri E
    Radiol Med; 1997 Oct; 94(4):362-70. PubMed ID: 9465244
    [No Abstract]   [Full Text] [Related]  

  • 15. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy.
    Lipp RW; Silly H; Ranner G; Dobnig H; Passath A; Leb G; Krejs GJ
    J Nucl Med; 1995 Jan; 36(1):13-8. PubMed ID: 7799065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences.
    Scheidhauer K; Hildebrandt G; Luyken C; Schomäcker K; Klug N; Schicha H
    Horm Metab Res Suppl; 1993; 27():59-62. PubMed ID: 8330874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
    Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
    J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors.
    Modlin IM; Cornelius E; Lawton GP
    Arch Surg; 1995 Apr; 130(4):367-73; discussion 373-4. PubMed ID: 7710334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
    Otte A; Jermann E; Behe M; Goetze M; Bucher HC; Roser HW; Heppeler A; Mueller-Brand J; Maecke HR
    Eur J Nucl Med; 1997 Jul; 24(7):792-5. PubMed ID: 9211767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.
    Slooter GD; Mearadji A; Breeman WA; Marquet RL; de Jong M; Krenning EP; van Eijck CH
    Br J Surg; 2001 Jan; 88(1):31-40. PubMed ID: 11136306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.